Merck KGaA Expects R&D Costs to Normalize in Line With Peers, CEO Says -- Market Talk

Dow Jones
03/06

1150 GMT - Merck KGaA anticipates its research and development costs will normalize to industry-peer levels as its pipeline advances and recent deals mature, Chief Executive Officer Belen Garijo says in a media call. The life-sciences and electronics company's R&D spending was 2.3 billion euros in 2024, and it expects it to gradually increase in 2025. Garijo reaffirms Merck's strategy to bolster in-licensing--agreements to use another company's products--and consider smaller mergers and acquisitions to strengthen its pipeline. Merck is looking for new assets as one of its key growth drivers, multiple sclerosis drug Mavenclad, will face patent expiry in 2026. The German company's goal is to achieve a 50-50 split between internal and external innovation for future product launches, Garijo adds. Shares are up 1.6% at 139.30 euros. (helena.smolak@wsj.com)

 

(END) Dow Jones Newswires

March 06, 2025 06:50 ET (11:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10